Moo H. Kim
Expertise in
5
conditions

Moo H. Kim

Seoul, KR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Seoul, KR 

Overview

Moo Kim practices practicing medicine in Seoul, Republic of Korea.

Mr. Kim is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Heart Attack, Coronary Heart Disease, Coronary Artery Spasm, Percutaneous Coronary Intervention (PCI), and Angioplasty.

He is actively involved in clinical research, co-authoring 248 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Seoul, Republic of Korea
Other Locations
Busan, Republic of Korea
Wondu, Republic of Korea
Ulsan, Republic of Korea
Daegu, Republic of Korea
Republic of Korea
Cheongju-si, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

EASTYLE (DE-escAlation Strategy for Optimal Ticagrelor Therapy in Acute MYocardiaL Infarction PatiEnts, Prospective, Multicenter, Randomized) Trial
EASTYLE (DE-escAlation Strategy for Optimal Ticagrelor Therapy in Acute MYocardiaL Infarction PatiEnts, Prospective, Multicenter, Randomized) Trial
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Ticagrelor
Study Phase: Phase 4
Phase 3 Study Comparing the Efficacy and Safety of Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.
Phase 3 Study Comparing the Efficacy and Safety of Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.
Enrollment Status: Completed
Publish Date: February 11, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

248 Total Publications

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.
Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.
Journal: Journal of the American Heart Association
Published: April 28, 2026

Frequently Asked Questions about Moo H. Kim

Is Moo H. Kim a top-rated expert for Percutaneous Coronary Intervention (PCI)?

MediFind is an objective health platform that identifies experts based on real-world data. Moo H. Kim is classified as an Distinguished expert for Percutaneous Coronary Intervention (PCI), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Moo H. Kim participate in research or clinical trials?

Yes. Moo H. Kim has published 248 articles and abstracts on conditions like Percutaneous Coronary Intervention (PCI). You can view a list of Moo H. Kim's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kim's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile